The stock of Uniqure NV (NASDAQ:QURE) hit a new 52-week low and has $6.04 target or 13.00% below today’s $6.94 share price. The 9 months bearish chart indicates high risk for the $166.86 million company. The 1-year low was reported on Oct, 28 by Barchart.com. If the $6.04 price target is reached, the company will be worth $21.69M less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 102,358 shares traded hands. Uniqure NV (NASDAQ:QURE) has declined 41.03% since March 28, 2016 and is downtrending. It has underperformed by 45.74% the S&P500.
Uniqure NV (NASDAQ:QURE) Ratings Coverage
Out of 9 analysts covering uniQure N.V. (NASDAQ:QURE), 9 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. uniQure N.V. has been the topic of 18 analyst reports since August 7, 2015 according to StockzIntelligence Inc. Roth Capital maintained Uniqure NV (NASDAQ:QURE) on Monday, September 21 with “Buy” rating. The stock of Uniqure NV (NASDAQ:QURE) has “Buy” rating given on Thursday, August 27 by Chardan Capital Markets. Piper Jaffray maintained the stock with “Buy” rating in Monday, September 21 report. Chardan Capital Markets maintained it with “Buy” rating and $40 target price in Thursday, October 1 report. Roth Capital reinitiated the shares of QURE in a report on Monday, November 30 with “Buy” rating. As per Tuesday, December 1, the company rating was initiated by Janney Capital. The firm earned “Overweight” rating on Friday, August 28 by Piper Jaffray. The stock has “Buy” rating given by Zacks on Tuesday, September 1. WallachBeth Capital maintained it with “Buy” rating and $35 target price in Wednesday, June 15 report. WallachBeth Capital maintained the stock with “Buy” rating in Tuesday, December 1 report.
According to Zacks Investment Research, “UNIQURE B.V. is involved in developing gene therapy for patients of genetic or acquired diseases. It offers Glybera for the treatment of lipoprotein lipase deficiency, an orphan metabolic disease. The company’s product pipeline includes which are in clinical trials are additional adeno-associated virus consist of AMT-060, AMT-021, AMT-110 and AAV2/glial. UNIQURE B.V. is headquartered in Amsterdam, the Netherlands.”
More news for Uniqure NV (NASDAQ:QURE) were recently published by: Fool.com, which released: “Why uniQure NV Stock Skyrocketed Today” on April 06, 2015. Marketwatch.com‘s article titled: “/quotes/zigman/3870025/realtime” and published on February 05, 2014 is yet another important article.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.